Online citations, reference lists, and bibliographies.
← Back to Search

Pharmacokinetics And Pharmacodynamics Of Promising Arginase Inhibitors

K. Abdelkawy, Kelsey Lack, F. Elbarbry
Published 2016 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Up-regulation of arginase activity in several chronic disease conditions, including cancer and hypertension, may suggest new targets for treatment. Recently, the number of new arginase inhibitors with promising therapeutic effects for asthma, cancer, hypertension, diabetes mellitus, and erectile dysfunction has shown a remarkable increase. Arginase inhibitors may be chemical substances, such as boron-based amino acid derivatives, α-difluoromethylornithine (DMFO), and Nω-hydroxy-nor-l-arginine (nor-NOHA) or, of plant origin such as sauchinone, salvianolic acid B (SAB), piceatannol-3-O-β-d-glucopyranoside (PG) and obacunone. Despite their promising therapeutic potential, little is known about pharmacokinetics and pharmacodynamics of some of these agents. Several studies were conducted in different animal species and in vitro systems and reported significant differences in pharmacokinetics and pharmacodynamics of arginase inhibitors. Therefore, extra caution should be considered before extrapolating these studies to human. Physicochemical and pharmacokinetic profiles of some effective arginase inhibitors make it challenging to formulate stable and effective formulation. In this article, existing literature on the pharmacokinetics and pharmacodynamics of arginase inhibitors were reviewed and compared together with emphasis on possible drug interactions and solutions to overcome pharmacokinetics challenges and shortage of arginase inhibitors in clinical practice.
This paper references
10.1183/09031936.00057710
Increased arginase activity contributes to airway remodelling in chronic allergic asthma
H. Maarsingh (2011)
10.1152/ajpheart.00560.2010
Arginase inhibition restores in vivo coronary microvascular function in type 2 diabetic rats.
J. Grönros (2011)
10.1038/14929
Arginase–boronic acid complex highlights a physiological role in erectile function
J. D. Cox (1999)
10.1136/gut.2004.042317
Citrulline increases arginine pools and restores nitrogen balance after massive intestinal resection
S. Osowska (2004)
10.4196/kjpp.2014.18.2.95
Korean Red Ginseng Water Extract Restores Impaired Endothelial Function by Inhibiting Arginase Activity in Aged Mice
Kwanhoon Choi (2014)
10.1152/ajpheart.00196.2009
ERM protein moesin is phosphorylated by advanced glycation end products and modulates endothelial permeability.
X. Guo (2009)
10.1016/0305-0491(95)02138-8
Comparative properties of arginases.
C. P. Jenkinson (1996)
10.1007/s12272-013-0125-3
Arginase II inhibitory activity of flavonoid compounds from Scutellaria indica
S. Kim (2013)
10.1016/j.urology.2007.12.002
Nitric oxide-mediated suppression of detrusor overactivity by arginase inhibitor in rats with chronic spinal cord injury.
K. Sasatomi (2008)
10.1111/j.1476-5381.2011.01584.x
Oxidative species increase arginase activity in endothelial cells through the RhoA/Rho kinase pathway
S. Chandra (2012)
Über die Arginase. Hoppe-Seyleŕs Zeitschrift für physiologische Chemie
A Kossel (1904)
10.1006/BBRC.2001.4874
Increased expression of arginase II in human diabetic corpus cavernosum: in diabetic-associated erectile dysfunction.
T. Bivalacqua (2001)
10.1016/J.YJMCC.2004.05.004
Arginase pathway in human endothelial cells in pathophysiological conditions.
T. Bachetti (2004)
10.1039/c0ob01117g
Prodrug design for the potent cardiovascular agent Nω-hydroxy-L-arginine (NOHA): synthetic approaches and physicochemical characterization.
D. Schade (2011)
10.1515/BCHM2.1904.41.4.321
Über die Arginase.
A. Kossel (1904)
10.1016/j.dmpk.2015.10.005
Pharmacokinetics of catechols in human subjects intravenously receiving XueBiJing injection, an emerging antiseptic herbal medicine.
Xiuxue Li (2016)
10.1007/s12272-009-1517-2
Bioavailability of salvianolic acid B and effect on blood viscosities after oral administration of salvianolic acids in beagle dogs
Dong-yan Gao (2009)
Small-molecule arginase inhibitors . Pharm Pat Anal
Ya Ivanenkov (2014)
10.1093/JN/116.8.1464
Tissue amino acids in rats fed norleucine, norvaline, homoarginine or other amino acid analogues.
J. Tews (1986)
Pharmacokinetics and tissue distribution of 2,3,5,4 0 -tetrahydroxystilbene-2-O-beta-D- glucoside from traditional Chinese medicine Polygonum multiflorum following oral administration to rats
G Lv (2011)
10.1152/ajpheart.1998.274.1.H342
Arginase modulates nitric oxide production in activated macrophages.
C. I. Chang (1998)
10.1007/BF00203544
Phase I trial and pharmacokinetic study of intravenous and oral α-Difluoromethylornithine
ConstanceA. Griffin (2004)
10.1152/ajpregu.1998.275.4.R1256
N G-hydroxy-l-arginine and nitric oxide inhibit Caco-2 tumor cell proliferation by distinct mechanisms.
G. Buga (1998)
Further studies on difluoromethylornithine in African trypanosomes.
P. McCann (1981)
10.1113/jphysiol.2007.128959
Up‐regulation of arginase activity contributes to attenuated reflex cutaneous vasodilatation in hypertensive humans
Lacy A. Holowatz (2007)
10.4268/cjcmm20150831
[Study on compatibility of Salviae Miltiorrhizae Radix et Rhizoma and Chuanxiong Rhizoma based on pharmacokinetics of effective components salvianolic acid B and ferulic acid in rat plasma].
C. Zhang (2015)
Arginase activity in human breast cancer cell lines: N(omega)-hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells.
R. Singh (2000)
10.1182/BLOOD.V114.22.3846.3846
Tanespimycin Reverses Bortezomib-Induced Inhibition of Granulopoiesis.
B. Car (2009)
10.1016/j.jvs.2008.02.030
Arginase blockade lessens endothelial dysfunction after thrombosis.
Chandani M Lewis (2008)
10.1021/JA971312D
Inhibition of Mn2+2-Arginase by Borate Leads to the Design of a Transition State Analogue Inhibitor, 2(S)-Amino-6-boronohexanoic Acid
R. Baggio (1997)
Inhibitory effect of salvianolate on human cytochrome P450 3A4 in vitro involving a noncompetitive manner.
Chong-zhen Qin (2015)
10.1016/j.atherosclerosis.2012.12.014
Arginase inhibition prevents the low shear stress-induced development of vulnerable atherosclerotic plaques in ApoE-/- mice.
V. Olivon (2013)
10.1146/ANNUREV.NUTR.22.110801.140547
Regulation of enzymes of the urea cycle and arginine metabolism.
S. M. Morris (2002)
10.1007/s11010-010-0515-5
Endothelial arginase II responds to pharmacological inhibition by elevation in protein level
Karina Y Krotova (2010)
10.4268/cjcmm20151231
[Pharmacokinetics of loganin, ferulic acid and stilbene glucoside in Bushen Tongluo formula in vivo].
Xiang-dan Liu (2015)
[Study on the metabolite of stilbene glucoside in mice by liquid chromatography tandem-mass spectrometry].
Jiang-hao Sun (2003)
[Intestinal absorption properties of three components in salvianolic acid extract and the effect of borneol on their absorption in rats].
Xiao-juan Lai (2010)
10.4149/gpb_2013078
Single- and multiple-dose pharmacokinetics of arginase inhibitor Nω-hydroxy-nor-L-arginine, and its effect on plasma amino acids concentrations in Wistar rats.
Z. Havlínová (2014)
10.1046/j.1365-2567.2003.01713.x
Arginase and autoimmune inflammation in the central nervous system
L. Xu (2003)
10.1124/dmd.108.021030
Inhibitory Effects of Seven Components of Danshen Extract on Catalytic Activity of Cytochrome P450 Enzyme in Human Liver Microsomes
Furong Qiu (2008)
10.1248/bpb.b14-00524
Pharmacokinetics, tissue distribution, and tentative metabolite identification of sauchinone in mice by microsampling and HPLC-MS/MS methods.
Y. Kim (2015)
10.1002/bmc.2681
Quantitative determination of sauchinone in rat plasma by liquid chromatography-mass spectrometry.
C. Xu (2012)
10.4268/cjcmm20130624
[Study on absorption location of four components from Naoxintong capsule].
Bin Huang (2013)
10.1021/bi002318
Mechanistic and metabolic inferences from the binding of substrate analogues and products to arginase.
J. D. Cox (2001)
10.1007/BF02783147
Comparative toxicology of borates
S. A. Hubbard (2007)
10.1021/jm100306a
2-aminoimidazole amino acids as inhibitors of the binuclear manganese metalloenzyme human arginase I.
M. Ilieș (2010)
10.1016/S0890-6238(02)00057-6
Effect of L-arginine on arginase activity in male accessory sex glands of alloxan-treated rats.
J. Méndez (2002)
10.1016/j.mvr.2014.11.002
Arginase inhibition enhances angiogenesis in endothelial cells exposed to hypoxia.
L. Wang (2015)
10.1002/BMC.408
HPLC determination and pharmacokinetic studies of salvianolic acid B in rat plasma after oral administration of Radix Salviae Miltiorrhizae extract.
J. Zhang (2005)
10.1111/J.1743-6109.2007.00518.X
A mouse model of hypercholesterolemia-induced erectile dysfunction.
Donghua Xie (2007)
10.1093/cvr/cvp303
Arginase inhibition mediates cardioprotection during ischaemia-reperfusion.
C. Jung (2010)
10.1016/J.BMC.2005.01.053
Synthesis and evaluation of new ω-borono-α-amino acids as rat liver arginase inhibitors
Olivier Busnel (2005)
10.1038/clpt.1981.150
Kinetics of α‐difluoromethylornithine: An irreversible inhibitor of ornithine decarboxylase
K. Hägele (1981)
Pharmacokinetic studies of alpha-difluoromethylornithine in rabbits using an enzyme-linked immunosorbent assay.
P. C. Gunaratna (1994)
10.1007/s11010-015-2611-z
Arginase inhibitor attenuates pulmonary artery hypertension induced by hypoxia
Yanbiao Chu (2015)
10.3892/IJO.32.2.357
Expression of arginase II in prostate cancer.
Shannon M. Mumenthaler (2008)
10.3389/fimmu.2013.00293
Selective Up-Regulation of Arginase-1 in Coronary Arteries of Diabetic Patients
Z. Bagi (2013)
Phase I trial and pharmacokinetic study of intravenous and oral alpha-difluoromethylornithine.
C. Griffin (1987)
10.1042/BJ3360001
Arginine metabolism: nitric oxide and beyond.
G. Wu (1998)
10.1021/bi034340j
Human arginase II: crystal structure and physiological role in male and female sexual arousal.
E. Cama (2003)
10.1097/HJH.0b013e3282fcc357
Treatment with the arginase inhibitor Nω-hydroxy-nor-L-arginine improves vascular function and lowers blood pressure in adult spontaneously hypertensive rat
Teddy Bagnost (2008)
Synthesis and evaluation of new omega-borono-alpha-amino acids as rat liver arginase inhibitors.
Olivier Busnel (2005)
10.1016/j.jchromb.2013.03.018
Simultaneous determination of limonin, dictamnine, obacunone and fraxinellone in rat plasma by a validated UHPLC-MS/MS and its application to a pharmacokinetic study after oral administration of Cortex Dictamni extract.
P. Wang (2013)
10.1096/fj.04-2317fje
Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension
W. Xu (2004)
10.1016/0014-5793(96)01015-0
Molecular cloning of cDNA for nonhepatic mitochondrial arginase (arginase II) and comparison of its induction with nitric oxide synthase in a murine macrophage‐like cell line
T. Gotoh (1996)
10.1006/NIOX.2001.0355
Effects of arginase isoforms on NO Production by nNOS.
L. Que (2002)
Bioavailability Study of Oral Liquid and Tablet Forms of α-Difluoromethylornithine
P. Carbone (2000)
10.3109/10715762.2010.527337
Piceatannol is more effective than resveratrol in restoring endothelial cell dimethylarginine dimethylaminohydrolase expression and activity after high-glucose oxidative stress
Matthieu Frombaum (2011)
10.1021/jm400014c
Discovery of (R)-2-amino-6-borono-2-(2-(piperidin-1-yl)ethyl)hexanoic acid and congeners as highly potent inhibitors of human arginases I and II for treatment of myocardial reperfusion injury.
M. V. Van Zandt (2013)
10.1002/rcm.7365
Comparative metabolism of four limonoids in human liver microsomes using ultra-high-performance liquid chromatography coupled with high-resolution LTQ-Orbitrap mass spectrometry.
W. Ren (2015)
10.1161/CIRCRESAHA.107.157727
Inducible NO Synthase–Dependent S-Nitrosylation and Activation of Arginase1 Contribute to Age-Related Endothelial Dysfunction
L. Santhanam (2007)
10.1016/j.bbrc.2015.07.048
Arginase inhibition ameliorates adipose tissue inflammation in mice with diet-induced obesity.
Huan Hu (2015)
10.5142/jgr.2013.37.64
Korean red ginseng inhibits arginase and contributes to endotheliumdependent vasorelaxation through endothelial nitric oxide synthase coupling
Woosung Shin (2013)
10.3724/SP.J.1009.2013.00560
The identification and pharmacokinetic studies of metabolites of salvianolic acid B after intravenous administration in rats: The identification and pharmacokinetic studies of metabolites of salvianolic acid B after intravenous administration in rats
Q. Qi (2014)
10.4155/ppa.13.75
Small-molecule arginase inhibitors.
Y. Ivanenkov (2014)
10.1186/s12871-016-0288-9
Erratum to: The effects of arginase inhibitor on lung oxidative stress and inflammation caused by pneumoperitoneum in rats
J. S. Cho (2016)
10.3389/fimmu.2013.00278
Development of Novel Arginase Inhibitors for Therapy of Endothelial Dysfunction
J. Steppan (2013)
10.1074/JBC.M303900200
Protein Kinase Cα-Induced p115RhoGEF Phosphorylation Signals Endothelial Cytoskeletal Rearrangement*
Michael Holinstat (2003)
10.1016/0021-9673(95)00604-L
Determination of alpha-difluoromethylornithine in blood by microdialysis sampling and capillary electrophoresis with UV detection.
T. Hu (1995)
10.1016/j.ejphar.2015.12.008
Treatment effect of l-Norvaline on the sexual performance of male rats with streptozotocin induced diabetes.
A. De (2016)
10.1124/jpet.111.190736
Salvianolic Acid B Exerts Vasoprotective Effects through the Modulation of Heme Oxygenase-1 and Arginase Activities
Y. Joe (2012)
10.1023/A:1003468726969
Immunohistochemical Localization of Arginase II and Other Enzymes of Arginine Metabolism in Rat Kidney and Liver
K. Miyanaka (2004)
10.1055/S-0029-1243113
Potentiating effect of obacunone from Dictamnus dasycarpus on cytotoxicity of microtuble inhibitors, vincristine, vinblastine and taxol.
H. Jung (2000)
10.1002/jcb.21422
Regulation of arginase‐1 expression in macrophages by a protein kinase a type I and histone deacetylase dependent pathway
Ivonne Haffner (2008)
10.4268/cjcmm20151532
[Absorption of aqueous extracts from Salviae Miltiorrhizae Radix et Rhizoma by everted intestinal sac method].
J. Zhao (2015)
10.1093/OXFORDJOURNALS.JBCHEM.A132579
Regulation of urea synthesis in rat liver. Inhibition of urea synthesis by L-norvaline.
T. Saheki (1979)
10.1007/BF01985654
Inhibition of arginase in sheep brain homogenates by some L-amino acids
P. U. Reddy (2005)
10.3233/CH-2012-1617
Increased arginase levels in heart failure represent a therapeutic target to rescue microvascular perfusion.
Felix Quitter (2013)
10.3858/emm.2010.42.7.053
Piceatannol-3'-O-β-D-glucopyranoside as an active component of rhubarb activates endothelial nitric oxide synthase through inhibition of arginase activity
Ainieng Woo (2010)
10.1006/NIOX.1999.0255
Effects of the new arginase inhibitor N(omega)-hydroxy-nor-L-arginine on NO synthase activity in murine macrophages.
J. Tenu (1999)
10.3109/00498254.2013.780672
Comparative pharmacokinetics of Nω-hydroxy-nor-L-arginine, an arginase inhibitor, after single-dose intravenous, intraperitoneal and intratracheal administration to brown Norway rats
Z. Havlínová (2013)
10.1097/01.hjh.0000166837.78559.93
Arginase inhibition reduces endothelial dysfunction and blood pressure rising in spontaneously hypertensive rats
C. Demougeot (2005)
10.1007/S11906-006-0041-8
Endothelial arginase: A new target in atherosclerosis
Z. Yang (2006)
10.1124/jpet.115.224592
A Novel Arginase Inhibitor Derived from Scutellavia indica Restored Endothelial Function in ApoE-Null Mice Fed a High-Cholesterol Diet
H. M. Hwang (2015)
10.1002/CHIN.200524290
Arginase: Structure, Mechanism, and Physiological Role in Male and Female Sexual Arousal
D. Christianson (2005)
10.1016/S0006-2952(97)00572-8
α-Difluoromethylornithine (DFMO) as a potent arginase activity inhibitor in human colon carcinoma cells
M. Selamnia (1998)
10.1016/j.jchromb.2011.11.022
HPLC determination of arginases inhibitor N-(ω)-hydroxy-nor-L-arginine using core-shell particle column and LC-MS/MS identification of principal metabolite in rat plasma.
M. Hroch (2012)
10.1152/AJPGI.00227.2006
Liver I/R injury is improved by the arginase inhibitor, Nω-hydroxy-nor-l-arginine (nor-NOHA)
K. Reid (2007)
10.1016/0014-2999(96)00163-X
Mechanisms mediating the vasodilatory effects of N-hydroxy-L-arginine in coronary arteries.
M. A. Abdul-Hussain (1996)
10.1038/ki.2013.215
Arginase inhibition mediates renal tissue protection in diabetic nephropathy by a nitric oxide synthase 3-dependent mechanism
Hanning You (2013)
10.1182/BLOOD.V114.22.1479.1479
A Systems Biology Approach to Study the Acquisition of Adult Repopulating Potential During Hematopoietic Stem Cell Ontogeny.
Shannon McKinney-Freeman (2009)
J Pharmacol Exp Ther
(2012)
10.1111/j.1743-6109.2007.00752.x
Adenosine actions are preserved in corpus cavernosum from obese and type II diabetic db/db mouse.
F. Carneiro (2008)
10.1016/j.bmcl.2013.06.092
Synthesis of quaternary α-amino acid-based arginase inhibitors via the Ugi reaction.
A. Golebiowski (2013)
10.1016/j.bmcl.2013.02.024
2-Substituted-2-amino-6-boronohexanoic acids as arginase inhibitors.
A. Golebiowski (2013)
10.1186/ar3860
Treatment with the arginase inhibitor Nw-hydroxy-nor-L-arginine restores endothelial function in rat adjuvant-induced arthritis
C. Prati (2012)
10.4268/CJCMM20122328
[Pharmacokinetic study on three main ingredients of refined coronary cataplasm].
Rui Hou (2012)
PK/PD of Promising Arginase Inhibitors
10.1161/01.CIR.0000142867.26182.32
Thrombin Stimulates Human Endothelial Arginase Enzymatic Activity via RhoA/ROCK Pathway: Implications for Atherosclerotic Endothelial Dysfunction
X. Ming (2004)
10.1016/J.EJPHAR.2005.04.021
Nomega-hydroxy-L-arginine homologues and hydroxylamine as nitric oxide-dependent vasorelaxant agents.
Petra Beranová (2005)
10.1042/BJ1530469
The heterogeneity of arginases in rat tissues.
A. Herzfeld (1976)
10.1016/J.NIOX.2014.09.129
P188 - Plasma arginase activity may affect the responses to sildenafil in patients with erectile dysfunction
R. Lacchini (2014)
10.2164/jandrol.111.015834
Chronic oral administration of the arginase inhibitor 2(S)-amino-6-boronohexanoic acid (ABH) improves erectile function in aged rats.
R. Segal (2012)
10.1161/CIRCULATIONAHA.112.140335
Arginase Inhibition Improves Endothelial Function in Patients With Coronary Artery Disease and Type 2 Diabetes Mellitus
A. Shemyakin (2012)
10.5012/BKCS.2012.33.9.3079
Arginase II Inhibitory Activity of Phenolic Compounds from Saururus chinensis
C. Lim (2012)
10.1111/j.1476-5381.2008.00036.x
The vascular effects of different arginase inhibitors in rat isolated aorta and mesenteric arteries
N. Huynh (2009)
10.1016/0022-2836(92)90479-4
Crystallization and oligomeric structure of rat liver arginase.
Z. Kanyo (1992)
10.1016/j.niox.2008.04.002
Arginase blockade protects against hepatic damage in warm ischemia-reperfusion.
G. Jeyabalan (2008)
10.1111/j.1440-1681.2007.04638.x
ARGINASE: A CRITICAL REGULATOR OF NITRIC OXIDE SYNTHESIS AND VASCULAR FUNCTION
W. Durante (2007)
10.1016/j.jep.2011.05.049
Pharmacokinetics and tissue distribution of 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside from traditional Chinese medicine Polygonum multiflorum following oral administration to rats.
Guiyuan Lv (2011)
10.1111/j.1476-5381.2009.00291.x
Arginase: an emerging key player in the mammalian immune system
M. Munder (2009)
10.4061/2011/515047
Arginase Inhibitor in the Pharmacological Correction of Endothelial Dysfunction
M. V. Pokrovskiy (2011)
10.1016/J.BBRC.2006.08.123
Reduction of Nω-hydroxy-l-arginine to l-arginine by pig liver microsomes, mitochondria, and human liver microsomes
B. Clement (2006)
10.2174/1389557515666150511153852
The Promise of Plant-Derived Substances as Inhibitors of Arginase.
C. Girard-Thernier (2015)
Reduction of Nomega-hydroxy-L-arginine to L-arginine by pig liver microsomes, mitochondria, and human liver microsomes.
B. Clement (2006)
10.1248/BPB.23.830
Metabolism of rhaponticin and chrysophanol 8-o-beta-D-glucopyranoside from the rhizome of rheum undulatum by human intestinal bacteria and their anti-allergic actions.
D. Kim (2000)
Biochemical and functional profile of a newly developed potent and isozyme-selective arginase inhibitor.
R. Baggio (1999)
10.1021/BI002317H
Probing erectile function: S-(2-boronoethyl)-L-cysteine binds to arginase as a transition state analogue and enhances smooth muscle relaxation in human penile corpus cavernosum.
N. Kim (2001)
10.1002/art.30391
Endothelial dysfunction in rat adjuvant-induced arthritis: up-regulation of the vascular arginase pathway.
C. Prati (2011)
Liver I/R injury is improved by the arginase inhibitor, N(omega)-hydroxy-nor-L-arginine (nor-NOHA).
K. Reid (2007)
Inhibition of polyamine metabolism : biological significance and basis for new therapies
P. McCann (1987)
10.4155/fso.15.53
Development and therapeutic applications of nitric oxide releasing materials to treat erectile dysfunction
K. Davies (2015)
10.1152/ajplung.00216.2009
Direct inhibition of arginase attenuated airway allergic reactions and inflammation in a Dermatophagoides farinae-induced NC/Nga mouse model.
N. Takahashi (2010)
10.3892/ijmm.2013.1261
Arginase inhibition by piceatannol-3'-O-β-D-glucopyranoside improves endothelial dysfunction via activation of endothelial nitric oxide synthase in ApoE-null mice fed a high-cholesterol diet.
Ainieng Woo (2013)
U ¨ ber die Arginase. Hoppe-SeylerSeyler´s Zeitschrift für physiologische Chemie
A Kossel (1904)
10.1111/j.1464-410X.2007.06860.x
Roles of attenuated neuronal nitric‐oxide synthase protein expression and accelerated arginase activity in impairing neurogenic relaxation of corpus cavernosum in aged rabbits
N. Numao (2007)
Alpha-difluoromethylornithine (DFMO) as a potent arginase activity inhibitor in human colon carcinoma cells.
M. Selamnia (1998)
10.1042/BJ20100960
Reduction of N(ω)-hydroxy-L-arginine by the mitochondrial amidoxime reducing component (mARC).
J. Kotthaus (2011)
10.1016/j.vph.2014.01.006
Endothelial nitric oxide synthase activation through obacunone-dependent arginase inhibition restored impaired endothelial function in ApoE-null mice.
Jeongyeon Yoon (2014)
10.1152/AJPHEART.00121.2005
Overexpression of arginase in the aged mouse penis impairs erectile function and decreases eNOS activity: influence of in vivo gene therapy of anti-arginase.
T. Bivalacqua (2007)
10.1016/S1875-5364(13)60101-6
The identification and pharmacokinetic studies of metabolites of salvianolic acid B after intravenous administration in rats.
Q. Qi (2013)
10.1093/jn/134.10.2873S
Role of arginase in the male and female sexual arousal response.
N. Kim (2004)
NGhydroxy-L-arginine and nitric oxide inhibit Caco-2 tumor cell K. S. Abdelkawy et al. proliferation by distinct mechanisms
Gm Buga (1998)
10.1161/CIRCRESAHA.107.155028
Diabetes-induced Coronary Vascular Dysfunction Involves Increased Arginase Activity
M. Romero (2008)
10.1006/BBRC.1994.2371
N omega-hydroxyl-L-arginine, an intermediate in the L-arginine to nitric oxide pathway, is a strong inhibitor of liver and macrophage arginase.
J. L. Boucher (1994)
Bioavailability study of oral liquid and tablet forms of alpha-difluoromethylornithine.
P. Carbone (2000)
10.1016/0731-7085(94)00064-6
Pharmacokinetic studies of α-difluoromethylornithine in rabbits using an enzyme-linked immunosorbent assay
P. C. Gunaratna (1994)
10.1016/0003-9861(55)90432-X
Metabolism of dl-norvaline-3-C14☆
D. S. Kinnory (1955)
10.1038/clpt.2008.302
Impact of Infectious and Inflammatory Disease on Cytochrome P450–Mediated Drug Metabolism and Pharmacokinetics
E. Morgan (2009)



This paper is referenced by
10.1016/j.exger.2018.12.011
The role of arginase in aging: A systematic review
J. Moretto (2019)
10.1016/j.phymed.2018.12.017
Piceatannol-3-O-β-D-glucopyranoside (PG) exhibits in vitro anti-metastatic and anti-angiogenic activities in HT1080 malignant fibrosarcoma cells.
A. Kim (2019)
10.37349/etat.2020.00014
Possible applications of salvianolic acid B against different cancers
Iram Shahzadi (2020)
10.1007/s11010-015-2611-z
Arginase inhibitor attenuates pulmonary artery hypertension induced by hypoxia
Yanbiao Chu (2015)
10.1681/ASN.2018010074
Interactions between Macrophages and Cyst-Lining Epithelial Cells Promote Kidney Cyst Growth in Pkd1-Deficient Mice.
Y. Yang (2018)
10.3390/ijms21155291
Arginase as a Potential Biomarker of Disease Progression: A Molecular Imaging Perspective
Gonçalo S Clemente (2020)
10.1016/j.ijcard.2019.11.004
Improvement in endothelial function in cardiovascular disease - Is arginase the target?
A. Mahdi (2019)
10.1016/j.bmc.2020.115658
Boronic acid-based arginase inhibitors in cancer immunotherapy.
Bartłomiej Borek (2020)
10.1016/j.bmcl.2017.12.044
Small molecule immuno-oncology therapeutic agents.
P. Toogood (2018)
10.1039/d0md00011f
Synthesis, evaluation and molecular modelling of piceatannol analogues as arginase inhibitors
J. Muller (2020)
10.1055/s-0044-100398
Phenolic Compounds as Arginase Inhibitors: New Insights Regarding Endothelial Dysfunction Treatment.
B. R. Minozzo (2018)
10.1371/journal.pone.0205254
The arginase inhibitor Nω−hydroxy−nor−arginine (nor−NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target
K. P. Ng (2018)
10.3389/fimmu.2020.00938
Myeloid Cell-Derived Arginase in Cancer Immune Response
Tomasz M. Grzywa (2020)
10.1007/s00726-018-2567-x
Arginase inhibition prevents the development of hypertension and improves insulin resistance in obese rats
K. Peyton (2018)
10.1186/s12871-015-0112-y
The effects of arginase inhibitor on lung oxidative stress and inflammation caused by pneumoperitoneum in rats
J. S. Cho (2015)
Semantic Scholar Logo Some data provided by SemanticScholar